Products
Research Areas
COVID-19
Resources
Login
Quick Order
Cart
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Contact Us

Locations


Orders Processing,
Shipping & Receiving,
Warehouse

2 Shaker Rd Suites
B001/B101
Shirley, MA 01464


Production Lab

Floor 6, Suite 620
20700 44th Avenue W
Lynnwood, WA 98036

Telephone Numbers



Tel: +1 (206) 374-1102
Fax: +1 (206) 577-4565

Contact Us



Additional Contact Details

Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order

MLXIPL / CHREBP

MLX interacting protein-like

MLXIPL / CHREBP is a basic helix-loop-helix leucine zipper transcription factor of the Myc/Max/Mad superfamily. This protein forms a heterodimeric complex and binds and activates, in a glucose-dependent manner, carbohydrate response element (ChoRE) motifs in the promoters of triglyceride synthesis genes. The gene is deleted in Williams-Beuren syndrome, a multisystem developmental disorder caused by the deletion of contiguous genes at chromosome 7q11.23.

Gene Name: MLX interacting protein-like
Synonyms: MLXIPL, CHREBP, MIO, MLX interactor, MLX interacting protein-like, MLX-interacting protein-like, MONDOB, WBSCR14, WS-bHLH, BHLHd14
Target Sequences: AF056184 AAD28084.1 Q9NP71

Publications (33)

1
Regulation of rat hepatic L-pyruvate kinase promoter composition and activity by glucose, n-3 polyunsaturated fatty acids, and peroxisome proliferator-activated receptor-alpha agonist. Xu J, Christian B, Jump DB. The Journal of biological chemistry. 2006 281:18351-62. [PubMed:16644726] [PMC:PMC2766394]
2
Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. Wang Y, Botolin D, Xu J, Christian B, Mitchell E, Jayaprakasam B, Nair MG, Nair M, Peters JM, Peters JM, Busik JV, Busik J, Olson LK, Jump DB. Journal of lipid research. 2006 47:2028-41. [PubMed:16790840] [PMC:PMC2764365]
3
Prenatal exposure to a low-protein diet programs disordered regulation of lipid metabolism in the aging rat. Erhuma A, Salter AM, Sculley DV, Langley-Evans SC, Bennett AJ. American journal of physiology. Endocrinology and metabolism. 2007 292:E1702-14. [PubMed:17299084] [PMC:PMC1890310]
4
The presence of distal and proximal promoters for rat mitochondrial glycerol-3-phosphate acyltransferase. Aneja KK, Guha P, Shilpi RY, Chakraborty S, Schramm LM, Haldar D. Archives of biochemistry and biophysics. 2008 470:35-43. [PubMed:18021946] [PMC:PMC2262852]
5
Elevated hepatic fatty acid elongase-5 activity affects multiple pathways controlling hepatic lipid and carbohydrate composition. Wang Y, Torres-Gonzalez M, Tripathy S, Botolin D, Christian B, Jump DB. Journal of lipid research. 2008 49:1538-52. [PubMed:18376007] [PMC:PMC2431109]
6
Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. Moon YA, Hammer RE, Horton JD. Journal of lipid research. 2009 50:412-23. [PubMed:18838740] [PMC:PMC2638104]
7
Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Kim HJ, Moradi H, Yuan J, Norris K, Vaziri ND. American journal of physiology. Renal physiology. 2009 296:F1297-306. [PubMed:19357177] [PMC:PMC2692452]
8
cAMP opposes the glucose-mediated induction of the L-PK gene by preventing the recruitment of a complex containing ChREBP, HNF4alpha, and CBP. Burke SJ, Collier JJ, Scott DK. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2009 23:2855-65. [PubMed:19406844]
9
Suppression of long chain acyl-CoA synthetase 3 decreases hepatic de novo fatty acid synthesis through decreased transcriptional activity. Bu SY, Mashek MT, Mashek DG. The Journal of biological chemistry. 2009 284:30474-83. [PubMed:19737935] [PMC:PMC2781602]
10
The glucose-responsive transcription factor ChREBP contributes to glucose-dependent anabolic synthesis and cell proliferation. Tong X, Zhao F, Mancuso A, Gruber JJ, Thompson CB. Proceedings of the National Academy of Sciences of the United States of America. 2009 106:21660-5. [PubMed:19995986] [PMC:PMC2799883]
11
Endotoxin, zymosan, and cytokines decrease the expression of the transcription factor, carbohydrate response element binding protein, and its target genes. Feingold KR, Shigenaga JK, Patzek SM, Chui LG, Moser A, Grunfeld C. Innate immunity. 2011 17:174-82. (WB; Mouse) [PubMed:20100709]
12
c-Myc is required for the CHREBP-dependent activation of glucose-responsive genes. Zhang P, Metukuri MR, Bindom SM, Prochownik EV, O'Doherty RM, Scott DK. Molecular endocrinology (Baltimore, Md.). 2010 24:1274-86. [PubMed:20382893] [PMC:PMC2875801]
13
ChREBP mediates glucose repression of peroxisome proliferator-activated receptor alpha expression in pancreatic beta-cells. Boergesen M, Poulsen Ll, Schmidt SF, Frigerio F, Maechler P, Mandrup S. The Journal of biological chemistry. 2011 286:13214-25. [PubMed:21282101] [PMC:PMC3075668]
14
O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Guinez C, Filhoulaud G, Rayah-Benhamed F, Marmier S, Dubuquoy C, Dentin R, Moldes M, Burnol AF, Yang X, Lefebvre T, Girard J, Postic C. Diabetes. 2011 60:1399-413. (WB, ChrIP; Mouse) [PubMed:21471514] [PMC:PMC3292313]
15
Identification of MIG12 as a mediator for stimulation of lipogenesis by LXR activation. Inoue J, Yamasaki K, Ikeuchi E, Satoh S, Fujiwara Y, Nishimaki-Mogami T, Shimizu M, Sato R. Molecular endocrinology (Baltimore, Md.). 2011 25:995-1005. [PubMed:21474539]
16
Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for ChREBP in glucose-regulated gene expression. Jeong YS, Kim D, Lee YS, Kim HJ, Han JY, Im SS, Chong HK, Kwon JK, Cho YH, Kim WK, Osborne TF, Horton JD, Jun HS, Ahn YH, Ahn SM, Cha JY. PloS one. 2011 6:e22544. [PubMed:21811631] [PMC:PMC3141076]
17
Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor?. Uebanso T, Taketani Y, Yamamoto H, Amo K, Ominami H, Arai H, Takei Y, Masuda M, Tanimura A, Harada N, Yamanaka-Okumura H, Takeda E. PloS one. 2011 6:e22976. [PubMed:21829679] [PMC:PMC3148241]
18
Glucose 6-phosphate, rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in the liver. Dentin R, Tomas-Cobos L, Foufelle F, Leopold J, Girard J, Postic C, Ferr P. Journal of hepatology. 2012 56:199-209. (WB; Mouse) [PubMed:21835137]
19
Krppel-like factor-10 is directly regulated by carbohydrate response element-binding protein in rat primary hepatocytes. Iizuka K, Takeda J, Horikawa Y. Biochemical and biophysical research communications. 2011 412:638-43. [PubMed:21856285]
20
Peroxisome proliferator-activated receptor- agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC. Journal of gastroenterology and hepatology. 2012 27:341-50. (WB; Mouse) [PubMed:21929649]
21
Low doses of bisphenol A induce gene expression related to lipid synthesis and trigger triglyceride accumulation in adult mouse liver. Marmugi A, Ducheix S, Lasserre F, Polizzi A, Paris A, Priymenko N, Bertrand-Michel J, Pineau T, Guillou H, Martin PG, Mselli-Lakhal L. Hepatology (Baltimore, Md.). 2012 55:395-407. [PubMed:21932408]
22
Elevated glucose represses liver glucokinase and induces its regulatory protein to safeguard hepatic phosphate homeostasis. Arden C, Petrie JL, Tudhope SJ, Al-Oanzi Z, Claydon AJ, Beynon RJ, Towle HC, Agius L. Diabetes. 2011 60:3110-20. [PubMed:22013014] [PMC:PMC3219956]
23
Liver Glucokinase(A456V) Induces Potent Hypoglycemia without Dyslipidemia through a Paradoxical Induction of the Catalytic Subunit of Glucose-6-Phosphatase. Vidal-Alabr A, Gmez-Valads AG, Mndez-Lucas A, Llorens J, Bartrons R, Bermdez J, Perales JC. International journal of endocrinology. 2011 2011:707928. [PubMed:22194744] [PMC:PMC3238378]
24
Rat glucagon receptor mRNA is directly regulated by glucose through transactivation of the carbohydrate response element binding protein. Iizuka K, Tomita R, Takeda J, Horikawa Y. Biochemical and biophysical research communications. 2012 417:1107-12. [PubMed:22198437]
25
Fructose 2,6-bisphosphate is essential for glucose-regulated gene transcription of glucose-6-phosphatase and other ChREBP target genes in hepatocytes. Arden C, Tudhope SJ, Petrie JL, Al-Oanzi ZH, Cullen KS, Lange AJ, Towle HC, Agius L. The Biochemical journal. 2012 443:111-23. (ICC, ChrIP; Rat) [PubMed:22214556]
26
PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. Perttil J, Huaman-Samanez C, Caron S, Tanhuanp K, Staels B, Yki-Jrvinen H, Olkkonen VM. American journal of physiology. Endocrinology and metabolism. 2012 302:E1063-9. (ChrIP; Human) [PubMed:22338072]
27
Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, Trapani F, Terracciano L, Heim MH, Regg MA, Hall MN. Cell metabolism. 2012 15:725-38. (WB; Mouse) [PubMed:22521878]
28
ChREBP mediates glucose-stimulated pancreatic -cell proliferation. Metukuri MR, Zhang P, Basantani MK, Chin C, Stamateris RE, Alonso LC, Takane KK, Gramignoli R, Strom SC, O'Doherty RM, Stewart AF, Vasavada RC, Garcia-Ocaa A, Scott DK. Diabetes. 2012 61:2004-15. [PubMed:22586588] [PMC:PMC3402328]
29
LRH-1-dependent glucose sensing determines intermediary metabolism in liver. Oosterveer MH, Mataki C, Yamamoto H, Harach T, Moullan N, van Dijk TH, Ayuso E, Bosch F, Postic C, Groen AK, Auwerx J, Schoonjans K. The Journal of clinical investigation. 2012 122:2817-26. (WB; Mouse) [PubMed:22772466] [PMC:PMC3408738]
30
Nrf2 deficiency improves glucose tolerance in mice fed a high-fat diet. Zhang YK, Wu KC, Liu J, Klaassen CD. Toxicology and applied pharmacology. 2012 264:305-14. (WB; Mouse) [PubMed:23017736] [PMC:PMC3507999]
31
Dysregulation of hepatic fatty acid metabolism in chronic kidney disease. Jin K, Norris K, Vaziri ND. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2013 28:313-20. (WB; Rat) [PubMed:23045433] [PMC:PMC3572771]
32
Hepatic FoxO1 integrates glucose utilization and lipid synthesis through regulation of Chrebp O-glycosylation. Ido-Kitamura Y, Sasaki T, Kobayashi M, Kim HJ, Lee YS, Kikuchi O, Yokota-Hashimoto H, Iizuka K, Accili D, Kitamura T. PloS one. 2012 7:e47231. (WB, IP; Mouse) [PubMed:23056614] [PMC:PMC3466224]
33
Glucose induces protein targeting to glycogen in hepatocytes by fructose 2,6-bisphosphate-mediated recruitment of MondoA to the promoter. Petrie JL, Al-Oanzi ZH, Arden C, Tudhope SJ, Mann J, Kieswich J, Yaqoob MM, Towle HC, Agius L. Molecular and cellular biology. 2013 33:725-38. (ChrIP; Rat) [PubMed:23207906] [PMC:PMC3571345]
more

☰ Filters
Products
Proteins (3)
Over-Expression Lysate (2)
Recombinant (1)
MLXIPL / CHREBP (3)
No (3)
GST, N-terminus (1)
Myc-DDK (Flag) (2)
Human (2)
293T Cells (1)
HEK 293 Cells (1)
Wheat Germ Extract (1)
MLXIPL / CHREBP Protein - Western validation with an anti-DDK antibody * L: Control HEK293 lysate R: Over-expression lysate
Select
293T Cells
Myc-DDK (Flag)
92.9 kDa
20 µg/$215
MLXIPL / CHREBP Protein - Western validation with an anti-DDK antibody * L: Control HEK293 lysate R: Over-expression lysate
Select
HEK 293 Cells
Myc-DDK (Flag)
92.9 kDa
100 µg/$710
MLXIPL / CHREBP Protein - 12.5% SDS-PAGE Stained with Coomassie Blue.
Select
Wheat Germ Extract
GST, N-terminus
10 µg/$479; 25 µg/$670
Viewing 1-3 of 3 product results


Filtered By:
Products: Proteins


If you do not find the reagent or information you require, please contact Customer.Support@LSBio.com to inquire about additional products in development.

PLEASE NOTE

For RESEARCH USE ONLY. Intended for use by laboratory professionals. Not intended for human diagnostic or therapeutic purposes.

The data on this page has been compiled from LifeSpan internal sources, the National Center for Biotechnology Information (NCBI), and The Universal Protein Resource (UniProt).